Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Summary: The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor involved in the proliferation and survival of cancer cells. EGFR is the first molecular target against which monoclonal antibodies (mAb) have been developed for cancer therapy. Here we review the mechanisms underlying the effects of EGFR-specific mAb in cancer therapy. The efficacy of EGFR-specific mAb in cancer occurs thanks to inhibition of EGFR-generated signalling; furthermore, the effects of antibodies on the immune system seem to play an important role in determining the overall anti-tumour response. In this review, attention is focused on cetuximab and panitumumab, two mAb introduced recently into clinical practice for treatment of metastatic colorectal and head and neck cancer which target the external part of EGFR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
The EGFR family and its ligands in human cancer
Yarden, Y. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00230-1 · Cited by 1,587
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Mayo, L. D., & Donner, D. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181181198 · Cited by 1,230
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
Nuclear localization of EGF receptor and its potential new role as a transcription factor
Lin, S.-Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-802 · Cited by 1,064
Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausova, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 946
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Gingras, A.-C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N., & Hay, N. (1998) · Genes & Development · doi:10.1101/gad.12.4.502 · Cited by 886
Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8135 · Cited by 850
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830
The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy
Woodburn, J. R. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00045-x · Cited by 827
De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm496 · Cited by 827
Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734
(2008) · Choice Reviews Online · doi:10.5860/choice.45-5565 · Cited by 648
Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., & Dinney, C. P. (1999) · PubMed · Cited by 647
What is trogocytosis and what is its purpose?
Joly, E., & Hudrisier, D. (2003) · Nature Immunology · doi:10.1038/ni0903-815 · Cited by 543
Mendez, M. J., Green, L. L., Corvalan, J. R. F., Jia, X.-C., Maynard-Currie, C. E., Yang, X.-D., Gallo, M. L., Louie, D. M., Lee, D. V., Erickson, K. L., et al. (1997) · Nature Genetics · doi:10.1038/ng0297-146 · Cited by 376
Van Cutsem, E., Lang, I., D'haens, G., Moiseyenko, V., Zaluski, J., Folprecht, G., Tejpar, S., Kisker, O., Stroh, C., & Rougier, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.2 · Cited by 372
Janmaat, M. L., Kruyt, F. A. E., Rodríguez, J. A., & Giaccone, G. (2003) · PubMed · Cited by 356
Tabernero, J., Van Cutsem, E., Díaz-Rubio, E., Cervantes, A., Humblet, Y., André, T., Van Laethem, J.-L., Soulié, P., Casado, E., Verslype, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.2183 · Cited by 337
Self-citationTarget-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Normanno, N., Bianco, C., De Luca, A., Maiello, M. R., & Salomon, D. S. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100001 · Cited by 336
Rowinsky, E. K., Schwartz, G. H., Gollob, J. A., Thompson, J. A., Vogelzang, N. J., Figlin, R., Bukowski, R., Haas, N., Lockbaum, P., Li, Y.-P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.061 · Cited by 329
Van Cutsem, E., Nowacki, M., Lang, I., Cascinu, S., Shchepotin, I., Maurel, J., Rougier, P., Cunningham, D., Nippgen, J., & Köhne, C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4000 · Cited by 313
Gille, J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.4.750 · Cited by 251
Epidermal growth factor receptor biology (IMC-C225)
Kim, E. S., Khuri, F. R., & Herbst, R. S. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00014 · Cited by 242
Bokemeyer, C., Bondarenko, I., Hartmann, J. T., De Braud, F. G., Volovat, C., Nippgen, J., Stroh, C., Celik, I., & Koralewski, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4000 · Cited by 240
Folprecht, G., Lutz, M. P., Schöffski, P., Seufferlein, T., Nolting, A., Pollert, P., & Köhne, C.-H. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj084 · Cited by 234
K-ras and p16 Aberrations Confer Poor Prognosis in Human Colorectal Cancer
Esteller, M., González, S., Risques, R. A., Marcuello, E., Mangues, R., Germà, J. R., Herman, J. G., Capellà, G., & Peinado, M. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.299 · Cited by 234
Jakobovits, A., Amado, R. G., Yang, X., Roskos, L., & Schwab, G. (2007) · Nature Biotechnology · doi:10.1038/nbt1337 · Cited by 230
Hudrisier, D., Riond, J., Mazarguil, H., Gairin, J. E., & Joly, E. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.6.3645 · Cited by 221
Thienelt, C. D., Bunn, P. A., Hanna, N., Rosenberg, A., Needle, M. N., Long, M. E., Gustafson, D. L., & Kelly, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1997 · Cited by 203
When kinases meet mathematics: the systems biology of MAPK signalling
Kolch, W., Calder, M., & Gilbert, D. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.02.002 · Cited by 177
Roda, J. M., Joshi, T., Butchar, J. P., McAlees, J. W., Lehman, A., Tridandapani, S., & Carson, W. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0865 · Cited by 146
Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies
Weiner, L. M., Belldegrun, A. S., Crawford, J., Tolcher, A. W., Lockbaum, P., Arends, R. H., Navale, L., Amado, R. G., Schwab, G., & Figlin, R. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1509 · Cited by 125
Borner, M., Koeberle, D., Von Moos, R., Saletti, P., Rauch, D., Hess, V., Trojan, A., Helbling, D., Pestalozzi, B., Caspar, C., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn058 · Cited by 124
Shepard, H. M., Brdlik, C. M., & Schreiber, H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36049 · Cited by 109
Wilke, H., Glynne-Jones, R., Thaler, J., Adenis, A., Preusser, P., Aguilar, E. A., Aapro, M. S., Esser, R., Loos, A. H., & Siena, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3758 · Cited by 104
Hudrisier, D., Aucher, A., Puaux, A., Bordier, C., & Joly, E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3637 · Cited by 102
Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., Zampino, M., Donea, S., Ludwig, H., Zubel, A., & Koralewski, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4035 · Cited by 101
Beum, P. V., Lindorfer, M. A., & Taylor, R. P. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2916 · Cited by 100
Berlin, J. D., Posey, J. A., Tchekmedyian, S., Hu, E. H.-L., Chan, D., Malik, I. A., Yang, L., Amado, R. G., & Hecht, J. R. (2007) · Clinical Colorectal Cancer · doi:10.3816/ccc.2007.n.011 · Cited by 95
Beum, P. V., Mack, D. A., Pawluczkowycz, A. W., Lindorfer, M. A., & Taylor, R. P. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.8120 · Cited by 94
Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC)
Malik, I. A., Hecht, J. R., Patnaik, A., Venook, A. P., Berlin, J. D., Croghan, G. A., Navale, L., MacDonald, M., Jerian, S., & Meropol, N. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3520 · Cited by 84
Antibody-Based Therapy for Solid Tumors
Yan, L., Hsu, K., & Beckman, R. A. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d71a · Cited by 71
Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy
Pennington, J., JACOBS, K. L. M., Sun, L., Bar‐Sela, G., Mishra, M. V., & Gius, D. R. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207782360537 · Cited by 69
(2011) · Springer eBooks · doi:10.1007/springerreference_35525 · Cited by 68
High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy
Zhang, Y., & Pastan, I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0324 · Cited by 67
Berlin, J., Neubauer, M., Swanson, P., Harker, W. G., Burris, H., Hecht, J. R., & Navale, L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3548 · Cited by 65
Hecht, J. R., Mitchell, E. P., Baranda, J. C., Malik, I. A., Richards, D., Navale, L., D'Avirro, P., & Amado, R. G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3547 · Cited by 58
Weiner, L. M., Belldegrun, A. S., Rowinsky, E. K., Crawford, J., Lockbaum, P., Huang, S.-F., Arends, R., Schwab, G., & Figlin, R. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3059 · Cited by 51
Tabernero, J. M., Cervantes, A. M. R., Martinelli, E., Vega-Villegas, E., Rojo, F., Fidalgo, J. A. P., Casado, E., Ciardiello, F., Zubel, A., & Baselga, J. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3085 · Cited by 37
Self-citationHumblet, Y., Vega-Villegas, E., Mesía, R., Awada, A. H., Geoffrois, L., Borel, C., Hitt, R., Amellal, N., Bessa, E., & Bourhis, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.5513 · Cited by 26
Borner, M., Mingrone, W. B., Koeberle, D., von Moos, R., Rauch, D., Saletti, P., Herrmann, R. P., Dietrich, D., Lanz, D., & Roth, A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3551 · Cited by 26
Oksvold, M. P., Huitfeldt, H. S., Stang, E., & Madshus, I. H. (2002) · Nature Cell Biology · doi:10.1038/ncb0202-e22a · Cited by 23
Monoclonal antibodies in the treatment of advanced colorectal cancer
Capdevila, J., Saura, C., Macarulla, T. M., Casado, E., Ramos, F. J., & Tabernero, J. M. (2007) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2007.09.025 · Cited by 22
Cervantes, A. M. R., Macarulla, T. M., Martinelli, E., Rodríguez-Braun, E., Ciardiello, F., Stroh, C., Nippgen, J., Baselga, J. M., & Tabernero, J. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4129 · Cited by 22
Self-citation
Cited by
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
“The first class of therapy developed includes humanized monoclonal antibodies against the EGFR extracellular domain, designed to block ligand binding or to mediate its downregulation [373].”
BackgroundUnderstanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683
Thatcher, N., Hirsch, F. R., Luft, A. V., Szczesna, A., Ciuleanu, T. E., Dediu, M., Ramlau, R., Galiulin, R. K., Bálint, B., Losonczy, G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00021-2 · Cited by 479
Ayati, A., Moghimi, S., Salarinejad, S., Safavi, M., Pouramiri, B., & Foroumadi, A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103811 · Cited by 379
PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.
Liao, H.-W., Hsu, J.-M., Xia, W., Wang, H.-L., Wang, Y.-N., Chang, W.-C., Arold, S. T., Chou, C.-K., Tsou, P.-H., Yamaguchi, H., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82826 · Cited by 155
Metadata
- Authors
- Martinelli, E., De Palma, R., Orditura, M., De Vita, F., & Ciardiello, F.
- Venue
- Clinical and Experimental Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-07-08
- Volume
- 158
- Issue
- 1
- Pages
- 1-9
- ISSN
- 0009-9104 (ISSN-L)
- 1365-2249
- OpenAlex
- W2039950956
- Cited by
- 333
- References
- 69
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.